Skip to content
Press Releases
Filter Releases
 
Press Releases
May 13, 2014
SOUTH SAN FRANCISCO, Calif., May 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo f...
PDF
May 8, 2014
SOUTH SAN FRANCISCO, Calif., May 8, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the first quarter ended March 31, 2014, and provided an update on recent business progress. For the first quarter of 2014, revenue was $7.5 million, an increase of 71%, compared to $4.4 million for the first quarter of 2013. ...
PDF
May 7, 2014
SOUTH SAN FRANCISCO, Calif., May 7, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced that early data demonstrating the company's ability to develop a molecular classifier differentiating interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), will be presented at the American Thoracic Society (ATS) 2014 Interna...
PDF
May 6, 2014
SOUTH SAN FRANCISCO, Calif., May 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that four abstracts supporting the use of the company's Afirma Malignancy Classifiers and enhancing its overall Afirma solution will be presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific & Clinical Con...
PDF
May 2, 2014
SOUTH SAN FRANCISCO, Calif. and SAO PAULO, Brazil, May 2, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) and Fleury Medicine and Health today announced a new partnership that will make Veracyte's Afirma Gene Expression Classifier (GEC) available to patients in Brazil, helping to reduce unnecessary surgeries and potentially lower costs there as ...
PDF
May 1, 2014
SOUTH SAN FRANCISCO, Calif., May 1, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its first quarter 2014 financial results will be released after close of market on Thursday, May 8, 2014.  Following the announcement, Veracyte's management will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the...
PDF
Mar 18, 2014
SOUTH SAN FRANCISCO, Calif., March 18, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today reported financial results and business progress for the quarter and full year ended December 31, 2013, and provided financial guidance for 2014. Revenue was $6.8 million for the fourth quarter of 2013, an increase of 53%, compared to 2012 fourth quarter...
PDF
Mar 17, 2014
SOUTH SAN FRANCISCO, Calif., March 17, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointments of two executives to its management team. Julie A. Brooks joins the company as executive vice president, general counsel and secretary; and Andy Thors...
PDF
Mar 11, 2014
SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2013 financial results after close of market on Tuesday, March 18, 2014. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the...
PDF
Mar 3, 2014
SOUTH SAN FRANCISCO, Calif., March 3, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced a change in the company's presentation date and time at the Cowen and Company 34th Annual Health Care Conference. Bonnie H. Anderson, president and chief executive officer, will present on Tuesday, March 4, 2014 at 8:00 a.m. ET in the St. Botolp...
PDF
Page: First Previous
...
Next Last